Esomeprazole/meloxicam - Axsome Therapeutics

Drug Profile

Esomeprazole/meloxicam - Axsome Therapeutics

Alternative Names: AXS 06

Latest Information Update: 14 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Axsome Therapeutics
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; 2 ring heterocyclic compounds; Amides; Analgesics; Antipyretics; Antiulcers; Gastric antisecretories; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 14 Aug 2017 Chemical structure information added
  • 25 Jul 2017 Topline pharmacokinetics and adverse events data from a phase I trial in Pain (Healthy volunteers) released by Axsome Therapeutics
  • 25 Jul 2017 Axsome Therapeutics completes a phase I pharmacokinetics trial in Pain (Healthy volunteers) in USA (PO) before July 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top